UMB Bank’s TG Therapeutics TGTX Stock Holding History

UMB Bank’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.1K	Buy	1,221 +105	+9%	+$4.3K	﹤0.01%	1201
2026 Q1	$37.1K	Buy	1,116 +33	+3%	+$983	﹤0.01%	1369
2025 Q4	$32.3K	Buy	1,083 +173	+19%	+$5.65K	﹤0.01%	1385
2025 Q3	$32.9K	Buy	910 +48	+6%	+$1.58K	﹤0.01%	1292
2025 Q2	$31K	Buy	862 +24	+3%	+$894	﹤0.01%	1256
2025 Q1	$33K	Buy	838 +149	+22%	+$5.01K	﹤0.01%	1206
2024 Q4	$20.7K	Buy	689 +427	+163%	+$12.3K	﹤0.01%	1241
2024 Q3	$6.13K	Buy	+262	New	+$5.72K	﹤0.01%	1664
2024 Q1	–	Sell	-796	Closed	-$13.6K	–	2188
2023 Q4	$13.6K	Buy	796 +213	+37%	+$2.48K	﹤0.01%	1191
2023 Q3	$4.87K	Hold	583	–	–	﹤0.01%	1427
2023 Q2	$14.5K	Buy	583 +386	+196%	+$9.97K	﹤0.01%	1187
2023 Q1	$2.96K	Hold	197	–	–	﹤0.01%	1482
2022 Q4	$2K	Hold	197	–	–	﹤0.01%	1574
2022 Q3	$1K	Hold	197	–	–	﹤0.01%	1709
2022 Q2	$1K	Buy	+197	New	+$1.23K	﹤0.01%	1869

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

UMB Bank's TGTX Position: Q2 2026 in Review

UMB Bank increased its TG Therapeutics (TGTX) stake by 9.4% in Q2 2026, buying an estimated $4.3K and bringing the position to 1,221 shares worth $67.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1201.

UMB Bank first reported a position in TGTX in Q2 2022 and has held it in 15 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

UMB Bank held 1,221 shares of TG Therapeutics worth $67.1K as of Q2 2026.
UMB Bank bought 105 TG Therapeutics shares in Q2 2026, an estimated $4.3K.
TG Therapeutics made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #1201 holding.
UMB Bank first reported a position in TG Therapeutics in Q2 2022 and has held it in 15 quarters since.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.